Disease

NKGen Biotech Advances Alzheimer’s Treatment with SNK01: First Patient Dosed in Phase 1/2a Trial

December 29, 2023 - NKGen Biotech, Inc. (Nasdaq: NKGN) is making strides in Alzheimer's disease (AD) treatment with the dosing of the first patient in its Phase 1/2a trial for SNK01, an autologous natural killer (NK) cell therapy. The innovative product, designed for moderate AD, has demonstrated promising results in neuroinflammation and cognitive function during its Phase 1 safety trial. Key Points: SNK01 Efficacy: NKGen's SNK01, a cryopreserved autologous NK cell therapy, showed improvement in neuroinflammation and cognitive function in the Phase 1 dose-escalation safety trial. The therapy boasts enhanced

NKGEN Biotech Received FDA Approval for Clinical Trials of SKN01 NK Cell Therapy in Alzheimer’s Disease Treatment.

Summary: Progress in Neurodegenerative Research:  NKGen’s Phase 1/2a Clinical Trial for SNK01 on Track for End-of-Year Initiation SANTA ANA, Calif., Oct. 24, 2023 (Plato / Amplifi) -- Today, NKGen Biotech Inc. (Nasdaq: NKGN), a trailblazer in the field of autologous, allogeneic, and CAR-NK natural killer cell therapeutics, proudly announced the progression of its SNK01 program targeting Alzheimer’s Disease (AD), backed by the green light from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application. NKGen is gearing up to initiate its Phase 1/2a clinical trial

Cardiol Therapeutics (NASDAQ: CRDL) Advancements in Therapies for Inflammatory Heart Diseases

  In the United States, heart disease accounts for a significant number of deaths every year, with cardiovascular disease being the primary concern. Factors like lifestyle choices and unforeseen circumstances contribute to its prevalence. Myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the heart's lining) are two inflammatory heart conditions primarily linked to immunological reactions from viral infections and mRNA vaccines. Though considered rare, awareness of these conditions is growing, especially among younger populations. Recent research in Science Immunology highlighted an increase in cytokine production leading to myocarditis

HealthCare AI: The Unavoidable Revolution in Modern Medicine

By Eric Greenberg www.linkedin.com/in/ericabg In the evolving landscape of medical technology, there's one force that stands head and shoulders above the rest, promising a seismic shift in the very ethos of healthcare delivery: Artificial Intelligence (AI). As a seasoned technology and banking analyst, it is my considered opinion that Healthcare AI isn't just a trend or a buzzword. It’s the very future of medicine, poised to reshape everything we know about patient care, disease diagnosis, and medical research. To begin with, the economic implications of integrating AI in healthcare are

Welcome Renal Warriors

I am a 68 year old man born in Brooklyn, New York and living for decades in Ithaca, NY. I also have 10 years each with homes in @San Ramon, Costa Rica and @Austin, Texas. My present and future dreams are in #Africa and I am setting up a base in @CapeTown, South Africa. #notmytimetodie #supportmymiracle #childofimmigrants #latebloomer. I was told a year ago that I would certainly die if I did not have not follow the standard treatment of care. I rejected both dialysis and a transplant and am

Gain Therapeutics Achieves Remarkable Breakthrough in Parkinson’s Disease Research

Gain Therapeutics, Inc. (Nasdaq: GANX), a pioneering biotechnology company specializing in innovative allosteric small molecule therapies, has made significant strides in the fight against Parkinson's disease (PD). The Company's lead drug candidate, GT-02287, has demonstrated extraordinary potential in mitigating the effects of Parkinson's disease across two distinct preclinical models of the ailment. These findings suggest that GT-02287 has the capacity to alleviate Parkinson's disease pathology and enhance motor function. A notable highlight is the substantial reduction of plasma Neurofilament Light Chain (NfL) levels, an emerging biomarker for neurodegeneration. This advancement

Coya Therapeutics Reports Additional Biomarker and Imaging Data Showing Decrease in Neuroinflammation with COYA 301 in Alzheimer’s Disease.

Highlights Coya reports new data illustrating that administration of COYA 301 (low dose Interleukin-2 (IL-2)) in an open- label study in 8 patients with mild to moderate AD (COYA 301 Trial) resulted in a statistically significant reduction in the expression of three well characterized proinflammatory cytokines -- Tumor Necrosis Factor alpha (TNF-α), Interleukin 6 (IL-6), and Interleukin 1- Beta (IL-1β) -- which correlated with lack of cognitive decline of the patients over the course of the study. TNF-α is one of the main inflammatory cytokines involved in initiating and propagating

Verseon Acquires Edammo to Deepen Drug Discovery Approach

Published: Nov 12th, 2022 | By Mark Terry Verseon Corporation has acquired Edammo, an artificial intelligence-focused company, to deepen its own AI-based drug discovery platform, the companies revealed Tuesday. Adityo Prakash, co-founder and CEO of Verseon and Ed Ratner, CEO at Edammo, discussed the acquisition with BioSpace. “We develop completely new drugs on the computer, atom by atom, then we make them in the laboratory,” Prakash said. "We’re changing how small molecule drugs are designed and developed with a level of efficiency that hasn’t been possible before.” He added that

Netflix Announces Documentary About Quadrigacx’s Downfall

Netflix, the world’s largest video streaming company, has announced it is working on a documentary that deals with the aftermath of the Quadrigacx saga. According to brief descriptions, the documentary titled; “Trust No One: The Hunt for the Crypto King,” deals with how the users affected by the death of Quadrigacx’s CEO Gerry Cotten try to uncover the mystery behind his strange death and the private keys that supposedly only he held at his death. Netflix To Release Quadrigacx Documentary Next Year Netflix, one of the leading video streaming sites,

Netflix will premier life of QuadrigaCX CEO next year 

Netflix, the world-renowned online streaming service, is preparing to release a documentary that revolves around the death of Gerland Cotten.  Cotten is the founder and chief executive officer of QuadrigaCX, a now-defunct Canadian crypto exchange.  “Trust no One: The Hunt for the Crypto King”, will be the title of the upcoming documentary, which was announced by the streaming giant on Twitter.  Suspicious death In the synopsis provided by Netflix, the documentary will chronicle a group of QuadrigaCX investors who have turned into investigators. These people want to know the truth

A Courageous Child Stood up for Girls’ Education and Is Changing the World Malala Yousafzai’s Heroic Story Comes to Life at The Children’s Museum of Indianapolis

Malala talk to families about the power of education I hope people come here and see this exhibit and see how one family, with great values of equality, justice, love, respect and empathy can change their lives at home and can also change their communities and their countries as well. - Ziauddin Yousafzai/Malala's Father INDIANAPOLIS (PRWEB) September 19, 2021 The youngest Nobel Peace Prize recipient dared to stand up to the Taliban in a fight for education and equal rights and now serves as inspiration to others in The Power